Literature DB >> 29564168

Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy.

William H Jin1,2, Eric A Mellon2, Jessica M Frakes2, Gilbert Z Murimwa1,2, Pamela J Hodul2, Jose M Pimiento2, Mokenge P Malafa2, Sarah E Hoffe2.   

Abstract

BACKGROUND: Total psoas area (TPA), a marker of sarcopenia, has been used as an independent predictor of clinical outcomes in gastrointestinal (GI) cancers as a proxy for frailty and nutritional status. Our study aimed to evaluate whether TPA, in contrast to traditional measurements of nutrition like body mass index (BMI) and body surface area (BSA), was predictive of outcomes in borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) patients receiving stereotactic body radiation therapy (SBRT).
METHODS: Retrospective analysis of an institutional review board approved database of 222 BRPC and LAPC treated with SBRT from 2009-2016 yielded 183 patients that met our selection criteria of pre-SBRT computed tomography (CT) imaging with an identifiable L4 vertebra. Once the L4 vertebral level was identified, the bilateral psoas muscles were manually contoured. This area was normalized by patient height, with units described in mm2/m2. Receiver operating characteristic (ROC) curves were generated for TPA, BMI, and BSA to elicit clinically relevant cutoffs. Regression and Kaplan-Meier analyses were used to correlate toxicity with survival functions.
RESULTS: Low TPA (OR =1.903, P=0.036) was predictive of acute toxicities, and only TPA was predictive of Grade 3 or higher acute toxicities (OR =10.24, P=0.007). Both findings were independent of tumor resectability. Pain (P=0.003), fatigue (P=0.040), and nausea (P=0.039) were significantly associated with low TPA. No association was identified between any measurement of nutritional status and the development of late toxicities, overall survival, local progression or local recurrence. However, BRPC patients survived longer (median =21.98 months) than their LAPC (median =16.2 months) counterparts (P=0.002), independent of nutritional status.
CONCLUSIONS: TPA measurement is readily available and more specific than BMI or BSA as a predictor of acute radiotoxic complications following SBRT in BRPC/LAPC patients. A TPA of <500 mm2/m2 is a clinically relevant cutoff that can direct physicians to address expected complications of pain, fatigue, and nausea. However, tumor resectability remains as the only predictor of overall survival in this cohort.

Entities:  

Keywords:  Pancreatic cancer; cachexia; computed tomography (CT); radiation toxicity; sarcopenia

Year:  2018        PMID: 29564168      PMCID: PMC5848029          DOI: 10.21037/jgo.2017.09.13

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  73 in total

1.  Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer.

Authors:  Irene Epelboym; J DiNorcia; M Winner; M K Lee; J A Lee; B A Schrope; J A Chabot; J D Allendorf
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

2.  Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.

Authors:  J L Cameron; D W Crist; J V Sitzmann; R H Hruban; J K Boitnott; A J Seidler; J Coleman
Journal:  Am J Surg       Date:  1991-01       Impact factor: 2.565

3.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

4.  Psoas muscle size as a frailty measure for open and transcatheter aortic valve replacement.

Authors:  Raghavendra Paknikar; Jeffrey Friedman; David Cron; G Michael Deeb; Stanley Chetcuti; P Michael Grossman; Stewart Wang; Michael Englesbe; Himanshu J Patel
Journal:  J Thorac Cardiovasc Surg       Date:  2015-11-21       Impact factor: 5.209

Review 5.  Therapeutic effects of anabolic androgenic steroids on chronic diseases associated with muscle wasting.

Authors:  Jorn Woerdeman; Willem de Ronde
Journal:  Expert Opin Investig Drugs       Date:  2011-01       Impact factor: 6.206

Review 6.  Aromatase activity and bone homeostasis in men.

Authors:  Luigi Gennari; Ranuccio Nuti; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2004-12       Impact factor: 5.958

7.  Cachexia worsens prognosis in patients with resectable pancreatic cancer.

Authors:  Jeannine Bachmann; Mathias Heiligensetzer; Holger Krakowski-Roosen; Markus W Büchler; Helmut Friess; Marc E Martignoni
Journal:  J Gastrointest Surg       Date:  2008-03-18       Impact factor: 3.452

8.  Histopathologic tumor response after induction chemotherapy and stereotactic body radiation therapy for borderline resectable pancreatic cancer.

Authors:  Michael D Chuong; Jessica M Frakes; Nicholas Figura; Sarah E Hoffe; Ravi Shridhar; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Gregory M Springett; Barbara A Centeno
Journal:  J Gastrointest Oncol       Date:  2016-04

9.  Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.

Authors:  Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

10.  Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer.

Authors:  David P J van Dijk; Maikel J A M Bakens; Mariëlle M E Coolsen; Sander S Rensen; Ronald M van Dam; Martijn J L Bours; Matty P Weijenberg; Cornelis H C Dejong; Steven W M Olde Damink
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-10-26       Impact factor: 12.910

View more
  5 in total

1.  Curative Radiotherapy in Elderly Patients With Muscle Invasive Bladder Cancer: The Prognostic Role of Sarcopenia.

Authors:  Gianluca Ferini; Alberto Cacciola; Silvana Parisi; Sara Lillo; Laura Molino; Consuelo Tamburella; Valerio Davi; Ilenia Napoli; Angelo Platania; Nicola Settineri; Giuseppe Iati; Antonio Pontoriero; Stefano Pergolizzi; Anna Santacaterina
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  Can sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal cancer? A systematic review and meta-analysis.

Authors:  Guangwei Sun; Yalun Li; Yangjie Peng; Dapeng Lu; Fuqiang Zhang; Xueyang Cui; Qingyue Zhang; Zhuang Li
Journal:  Int J Colorectal Dis       Date:  2018-07-10       Impact factor: 2.571

3.  Body Composition Influences Post-Operative Complications and 90-Day and Overall Survival in Pancreatic Surgery Patients.

Authors:  Sónia Velho; Maria Pia Costa Santos; Cátia Cunha; Lisa Agostinho; Rita Cruz; Filipe Costa; Mafalda Garcia; Paulo Oliveira; Rui Maio; Vickie E Baracos; Marília Cravo
Journal:  GE Port J Gastroenterol       Date:  2020-05-19

4.  Sarcopenia represents a negative prognostic factor in pancreatic cancer patients undergoing EUS celiac plexus neurolysis.

Authors:  Antonio Facciorusso; Matteo Antonino; Nicola Muscatiello
Journal:  Endosc Ultrasound       Date:  2020 Jul-Aug       Impact factor: 5.628

5.  A Single Axial Slice of the Sternocleidomastoids and Paravertebral Muscles Associated with Worse Local Progression-Free Survival and Severe Toxicity in Sarcopenic Head and Neck Cancer Patients Undergoing Radiotherapy.

Authors:  William Jin; Benjamin Rich; Raphael Yechieli; Laura Freedman; Michael A Samuels; Matthew Abramowitz; Ruben Carmona; Stuart E Samuels
Journal:  Cureus       Date:  2022-02-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.